Objective: Little is known about the influence of preterm delivery and perinatal risk factors on development and expression of the coagulation system in extremely preterm infants. The objective of this study was to determine reference values for the components of the coagulation system at the first day of life in extremely preterm infants.
Introduction
Coagulation protein synthesis in the embryo and fetus is independent from maternal coagulation proteins, as these do not cross the placental barrier. mRNA coding for specific coagulation proteins is present within hepatocytes of the human embryo and fetus at 5 to 10 weeks of gestational age (GA) and is detectable in the plasma of 8-to 10-week-old embryos and fetuses, respectively. 1 It is known that plasma concentration of coagulation factors changes depending on GA. [2] [3] [4] Reference values of the coagulation system of full-term infants and preterm infants with a GA of 30 to 36 weeks at birth are available. 2, 3 Data describing the coagulation system of extremely preterm infants are still scarce.
The aim of this study was to determine reference values for components of the coagulation system on the first day of life in extremely preterm infants of a GA <28 weeks. We hypothesized that perinatal risk factors independently influence the expression of coagulation factors at the time of birth.
Methods

Study design
This retrospective clinical cohort study comprises 132 extremely preterm infants born at completed 23 to 27 weeks of GA, treated at the perinatal center of the University Hospital of Bonn between 1 January 1999 and 31 August 2004. 174 infants were eligible for the study. Exclusion criteria were twin-to-twin transfusion syndrome and malformations. Hospital records of the patients and maternal birth protocols were reviewed. Collected data included day and time of birth, gender, GA, birth weight and maternal medical history during pregnancy. All data were anonymized before the analysis. GA at delivery was determined by first trimester ultrasound examination.
Study infants were grouped according to clinical criteria for preterm delivery: group A (maternal indication): pre-eclampsia or HELLP-syndrome (hemolysis, elevated liver enzymes, low platelet count), group B (uteroplacental dysfunction): uteroplacental insufficiency, cervix insufficiency or premature placental separation and group C (systemic inflammation): chorioamnionitis. Criteria for chorioamnionitis were a C-reactive protein value in the maternal serum of >20 g l À1 , a maternal leukocyte count >15 000 ml À1 and fever >38 1C within 3 days of delivery.
Coagulation tests were performed within the first hour of life before vitamin K administration (0.2 mg phytomenadione solution intravenous) exclusively as part of routine laboratory testing.
The measured components of the coagulation system included clottable concentration of fibrinogen, antithrombin, D-dimer and activities of factors II, V, VII, VIII and X. Blood samples were obtained by arterial puncture or from umbilical artery or vein catheter at routine blood check immediately after birth before heparinized fluid infusion. Collection tubes (500 ml) (Sarstedt, Nü mbrecht, Germany) contained 109 mmol l À1 (3.2%) trisodium citrate at a ratio of one volume sodium citrate and nine volumes blood. After centrifugation with 14 000 g for 3 min, platelet-poor plasma was immediately analyzed.
Fibrinogen was determined by the photocoagulometric Clauss method. Coagulation factor activities were assessed using commercially available coagulation factor-deficient plasmas based on a modified prothrombin time assay. Antithrombin was assayed by chromogenic anti-factor IIa method. D-dimer was analyzed by enzyme-linked immunosorbent assay. All reagents including immuno-depleted coagulation factor-deficient plasmas were purchased from Siemens Healthcare Diagnostics, Eschborn, Germany, prothrombin time reagent Innovin. Fibrinogen and antithrombin were determined by the automated coagulation analyzing systems Thrombolyzer (Behnk, Norderstedt, Germany) and ACL TOP (Instrumentation Laboratories, Kirchheim, Germany). D-dimer was measured by Vidas D-dimer Exclusion test on the VIDAS/mini VIDAS system (BioMérieux, Nü rtingen, Germany). The coagulometric assays for clotting factors II, V, VII, VIII and X were performed on the AMAX CS 190 system (Trinity Biotec, Lemgo, Germany). Activities of the clotting factors are reported as percentages, where 100% equals 1 IU ml À1 . For each duplicate testing the following volumes of citrate plasma were required: 2 Â 5 ml for clotting factors, 2 Â 8 ml for fibrinogen, and 2 Â 4 ml for the chromogenic antithrombin assay. Thus, including waste and void volumes less than 100 ml sample volume was necessary in total for each patient.
Data analysis
For statistical analysis Mann-Whitney U-test and w 2 test with twosided P-values were applied to compare values between two groups of patients. Kruskal-Wallis test was performed to compare more than two groups. Data were processed using statistical software SPSS 14.0 (SPSS, Chicago, IL, USA). A P-value <0.05 was taken as statistically relevant.
Ethics The study protocol was approved by the ethics committee of the Medical Faculty of the University of Bonn (048/08).
Results
The study population comprised 65 male and 67 female infants. The median age of gestation was 25 . The study population was categorized according to completed weeks of GA (23 weeks GA n ¼ 26; 24 weeks GA n ¼ 24; 25 weeks GA n ¼ 22; 26 weeks GA n ¼ 39; 27 weeks GA n ¼ 21). Table 1 presents neonatal data of the study population categorized by GA. No difference was found for gender distribution (P ¼ 0.28) or distribution of small for GA infants within the groups. Patients at completed 23 weeks GA received significantly less frequently prenatal steroids (P ¼ 0.008) and were more likely twin pregnancies (P ¼ 0.001). Table 2 presents the analyzed coagulation factors separated for every week of GA in comparison to data of a more mature group with a GA between 30 and 36 weeks at birth and those of full-term infants, both published by Andrew et al.
2,3
Levels of factors VII and X rose with increasing GA at birth (P<0.01 Kruskal-Wallis test). Values for both coagulation factors were significantly lower in infants born at 23 weeks of gestation compared with those born at 27 weeks of gestation (FVII P<0.007: FX P ¼ 0.038). Fibrinogen as well as the coagulation factors II, V and VIII did not differ significantly between the subgroups. Levels of factors V and VIII were higher than that of levels of vitamin Kdependent factors. Analysis of D-dimer and antithrombin levels related to GA did not show significant differences within the cohort (Kruskal-Wallis test: antithrombin P<0.6; D-dimer P<0.06). Table 3 summarizes the plasma concentrations of fibrinogen and the coagulation factors in three subgroups according to clinical criteria for preterm delivery. If preterm delivery was caused by placental disorder (group B) or chorioamnionitis (group C) the infants had significantly lower levels of factor II, VIII and X 
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Coagulation system in extremely preterm infants C Poralla et al (P ¼ 0.001), whereas factor V and VII levels were not different. Patients of group C had higher fibrinogen levels compared with group A (P ¼ 0.02). Antithrombin did not significantly differ between the three groups. D-dimer levels were lowest in group A and reached the highest values in group C (group A versus group C: P ¼ 0.09, group B versus group C: P ¼ 0.07). The study population (n ¼ 132) included 23 pairs of twins and 2 sets of triplets. In all, 15 of the 132 patients were small for GA (birth weight <3rd percentile). Analysis of the coagulation factors in the twin subgroup did not show intra-twin-pair differences.
Discussion
The results of this clinical study endorse the assumption of a lower synthesis of coagulation proteins in extremely preterm infants at the first day of life. When compared with healthy full-term infants examined by Andrew et al., 3 hemostatic parameters of the extremely preterm infants are significantly lower. We confirmed a GA dependency of the activity of vitamin K-dependent clotting factors II, VII and X. The clotting factor activities rise with increasing GA. Activities of factors VII and X were significantly higher in infants with a GA of 27 weeks compared with those with a GA of 23 weeks. This supports the hypothesis of a maturation of the coagulation system during pregnancy.
Consistent with the data obtained from fetuses, preterm and term infants, levels of factors V and VIII were higher than those of vitamin K-dependent factors.
2-5 Andrew et al. found only slight differences between the coagulation systems of healthy premature infants between 30 and 36 weeks of gestation and full-term infants. 2, 3 Thus, the period between 30 and 40 weeks of GA does not seem to be a time of rapid changes in the coagulation system. Our data and those from fetuses support the hypothesis that maturation of the coagulation system occurs earlier in fetal development. Reverdiau-Moalic et al. 4 observed considerable differences in the majority of blood coagulation factors in fetuses with an increase of factor VII comparable with our values but not of factor X. The significant changes of both factor VII and factor X might indicate that the activation of factor X via the extrinsic pathway has a major role in the coagulation system of fetuses and extremely preterm infants as compared with the adults.
Up to date, there are only few studies on coagulation factors in extremely preterm infants. 6, 7 The number of included extremely preterm infants <28 weeks GA in both studies is small (n ¼ 10 (ref. 6); n ¼ 21 (ref. 7) ). Therefore, interpretation of the findings and their impact on the perinatal risk of bleeding has to be done with caution. In accordance with our findings both studies demonstrate reduced coagulation factors in these patients. Additionally, Salonvaara et al.
7 observed distinct differences in coagulation factor profile among twin pairs and in small for GA The data refer to Andrew et al.
3 Table 3 Coagulation factor activities: study population grouped according to clinical criteria for preterm delivery: group A (maternal indication); group B (uteroplacental dysfunction); group C (chorioamnionitis) (median and range) patients when compared with those appropriate for GA. Our study population included 23 pairs of twins and 2 sets of triplets. Analysis of the coagulation factors in the twin subgroup did not show any intra-twin-pair differences. However, we were not able to retrospectively distinguish mono-versus di-chorionic in all of the twin pairs. In mono-chorionic twins feto-fetal transfusion syndrome with hemodynamic instability may presumably alter placental coagulation. The study by Salonvaara et al. 7 did not provide details on the chorion status. Therefore, interpretation of their findings is difficult.
Further studies examined postnatally coagulation factors in full-term infants and in preterm infants with a GA between 30 and 36 weeks, as well as prenatally in fetuses with a GA less than 30 weeks. However, regardless of GA coagulation factor levels are lower in fetuses than in infants shortly after birth. [2] [3] [4] It has been proposed that the birth process itself alters coagulation parameters. 4 Consequently it appears to be advisable to examine arterial blood samples of the neonate instead of cord blood samples.
The presented data describe coagulation factors early postnatal in a large cohort of 132 extremely preterm infants. The criterion 'less than 28 weeks of gestational age' was chosen to focus on those preterm infants who are at highest risk of bleeding complications, such as intraventricular hemorrhage, necrotizing enterocolitis and pulmonary hemorrhage. However, evaluation of our data as reference values may be limited by the sample size and inhomogenicity of the studied population. We also included all infants regardless of their illness. Previous studies have shown that even mild degrees of hypoxia or respiratory distress syndrome can affect levels of coagulation factors. 2 Patients included in our study were grouped according to the description of clinical risk factors acutely related to premature delivery, given by the obstetric team before delivery. Decision criteria included placental function parameters (ultrasound, Doppler) as well as maternal risk factors, such as HELLPsyndrome, pre-eclampsia and clinically defined chorioamnionitis. In case of coincidental risk factors (for example: intrauterine growth restriction and clinical suspicion of chorioamnionitis), grouping of the patients was performed by preferentially considering the risk factor most likely related to preterm delivery. We are aware that this might have underestimated the complexity of the individual risk profile. The aim of our study was to analyze the coagulation profile in extremely preterm infants and to identify those infants at highest risk of developing bleeding complications by adjusting for both perinatal clinical risk profile including materno-placental morbidity and neonatal morbidity. Further prospective studies should include placental histopathology and multiple gestation.
Our results give evidence that the coagulation system of extremely preterm infants is influenced by an individual perinatal risk profile.
Consistent with previous studies our data have shown only modest differences in hemostatic parameters of neonates born to mothers with pre-eclampsia (group A) compared with those after normal pregnancy. However, the samples of those studies were not drawn from the newborn but exclusively from the umbilical cord. 8, 9 Considering that the birth process itself alters several coagulation factors the results are not comparable. 4 If prematurity was caused by placental disorders (group B) or chorioamnionitis (group C), the infants had significantly lower levels of factors II, VIII and X when compared with the infants born to mothers with preeclampsia (group A), whereas factor V and VII levels were approximately equal. If prematurity was caused by infection, the fibrinogen levels were higher when compared with those in the other two groups, which is consistent with previous studies. 10 Fibrinogen belongs to the acute phase proteins, and might thus be separately regulated compared with the other coagulation factors.
It cannot be clearly distinguished whether the decreased coagulation factor levels in the chorioamnionitis group are due to a higher turnover rate or due to a diminished synthesis rate. Two aspects support the first hypothesis: first, the levels of coagulation factor V and also antithrombin that are synthesized in the liver independently from vitamin K are comparable in the three groups. Second, D-dimers as indicators of an activated coagulation system, and being potentially related to an increased turnover of coagulation factors, tend to be higher in group C than in both other groups. Though, antithrombin levels, which are frequently decreased due to increased turnover in situations associated with disseminated vascular coagulation, such as sepsis, are equal in the three groups. Consistent with previous studies on preterm infants 2, 4 levels of antithrombin were lower in our cohort compared with the values obtained from newborns. 3 Consequently this parameter might not be suitable to support or refute the latter hypothesis. Further research is required to assess the characteristics of the coagulation system in preterm infants, especially to determine whether the decreased coagulation factor levels are a result of a diminished synthesis rate and/or a higher turnover rate.
A meta-analysis comprising seven trials with 657 patients showed a significantly reduced risk of neonatal sepsis by 68% in mothers with premature rupture of the membranes prenatally treated with antibiotics.
11 This is highly clinically relevant, as neonatal sepsis is associated with mortality rates between 15 and 50% and increased risk of severe long-term neurological sequelae with the highest risk of a fatal outcome for extremely premature infants. 12 
Conclusion
Extremely preterm infants show a lower hemostatic profile when compared with term newborn infants and adults. Vitamin Kdependent coagulation factors rise with increasing GA. Perinatal risk factors like placental disorders and chorioamnionitis seem to interfere with coagulation protein synthesis and are associated with significantly lower levels of coagulation factor II, VIII and X, whereas pre-eclampsia obviously does not have a remarkable effect on the development of the infants' coagulation system. It remains to be shown whether prenatal antibiotic treatment of the mother may prevent the adverse effects chorioamnionitis on the infants' coagulation system.
